jpm
JPM delivered record Q1 markets revenue and 23% ROTCE while guiding to ~$103B NII. The question is whether premium execution justifies a premium price near fair value.
We're Neutral at 70/100 signal strength; base fair value is about $330 and the 12-month target is $340.
report snapshot
Q1 2026 delivered record Markets revenue ($11.6B), +10% revenue growth, and 23% ROTCE. Base fair value of $330 implies ~7.8% upside from $306; 12-month target $340 (+11.1%) reflects analyst consensus.
Q1 2026 delivered record Markets revenue ($11.6B), +10% revenue growth, and 23% ROTCE. Base fair value of $330 implies ~7.8% upside from $306; 12-month target $340 (+11.1%) reflects analyst consensus.
$306 · $810B · as of May 28, 2026.
Review filings-backed metrics in the financials section for the strongest evidence lines.
Numbers can look similar while narrative labels diverge — focus on which spreadsheet row the market is pricing.
variant perception & thesis
We rate JPMorgan Chase & Co. Neutral with conviction 70/100 . At $306 , the stock is already premium-priced at 14x earnings and 2.81x TBV , but the available 2025 annual and quarterly SEC EDGAR data still support upside because per-share intrinsic value compounded faster than the headline earnings line suggests. Our 12-month target is $340 , anchored by a base fair value of $330 and supported by 15.7% ROE , equity growth to $362.44B , and a share count decline from 2.80B to 2.70B .
1. Earnings Power Rate Credit Cycle
CatalystCan JPM sustain returns on equity/tangible common equity above its cost of equity as net interest income normalizes, loan growth slows, and credit costs move through the cycle...
2. Scale Moat Durability
Thesis PillarIs JPM's competitive advantage in deposits, distribution, brand, and multi-product scale durable enough to support superior profitability without triggering a persistent price or investment war...
3. Regulatory Capital Complexity Overhang
CatalystWill JPM's size and complexity lead to rising capital, regulatory, legal, or operational burdens that materially cap capital returns and valuation multiples...
4. Diversification Vs Hidden Concentration
Thesis PillarDoes JPM's business mix genuinely reduce earnings volatility, or are profits still economically concentrated in the most cyclical businesses such as consumer banking and CIB...
We believe JPM is worth about $340 over 12 months, or roughly 13.3% above the current $306 , because the market is underestimating how much 15.7% ROE plus a 3.6% reduction in shares outstanding can keep compounding per-share value even as earnings growth slows. That is Neutral for the thesis, but only moderately so because the stock already trades at 2.81x TBV and 14x earnings . We would change our mind if returns deteriorate enough to break the premium-multiple logic, specifically if ROE falls below 14.0% or annual diluted EPS falls below $18.00 .
| Criterion | Threshold | Actual Value | Pass/Fail |
|---|---|---|---|
Adequate size of enterprise | Large, seasoned company | Revenue $182.45B; Market cap $810B | Pass |
Strong financial condition | Conservative leverage and balance-sheet strength… | Debt to equity 0.74; Total liabilities to equity 11.21… | Fail |
Earnings stability | Positive earnings through a full cycle, traditionally 10 years… | Snapshot confirms 2025 annual diluted EPS $20.02 and profitable 2025 quarters, but not a full 10-year series… | — |
Dividend record | Long uninterrupted dividend history | — in the available filings snapshot… | — |
Earnings growth | At least one-third growth over 10 years | Only latest YoY EPS growth of +1.4% is disclosed… | — |
Moderate P/E | 15x or lower | P/E 14.6x | Pass |
financial analysis
| Metric | Value |
|---|---|
Revenue | $158.10B |
Revenue (2) | $177.56B |
FY2025 revenue | $182.45B |
Key Ratio | 12.3% |
Net income | $57.05B |
Net margin | 31.3% |
Net margin (2) | 15.7% |
Net income (2) | $14.64B |
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Revenues | $128.7B | $158.1B | $177.6B | $182.4B |
Net Income | $37.7B | $49.6B | $58.5B | $57.0B |
EPS (Diluted) | $12.09 | $16.23 | $19.75 | $20.02 |
Net Margin | 29.3% | 31.3% | 32.9% | 31.3% |
Important takeaway. JPM's most important non-obvious financial signal is that per-share earnings held up better than absolute profit because capital return offset slower growth. FY2025 net income declined 2.4% year over year, yet diluted EPS still increased 1.4% to $20.02 , helped by shares outstanding falling from 2.80B to 2.70B ...
valuation
| Parameter | Value |
|---|---|
Revenue (base) | $182.45B |
FCF Margin | 31.3% net margin anchor |
WACC | 10.1% |
Terminal Growth | 3.0% |
Template | bank equity DCF |
$250
FY2026 revenue assumption $180.63B and EPS $18.50 ...
$340
FY26 EPS ~$22.42, NII ~$103B guide, ROTCE stays high-teens...
$391
FY2026 revenue assumption $193.40B and EPS $22.50 ...
Important takeaway. JPM still screens modestly undervalued even though growth has slowed, because the market is paying for durability rather than acceleration. The key non-obvious support is that shares outstanding fell from 2.80B to 2.70B while ROE remained 15.7% ; that combination lets per-share value compound faster than the headline +2.8% revenue growth would suggest...
Method selection matters more than usual here. The DCF points to $330 , while the Monte Carlo mean shows -$263.34 , an obvious mismatch for a bank that earned $57.05B in FY2025. For JPM, valuation should be anchored primarily on earnings, book value, ROE, and capital return rather than industrial-style enterprise cash-flow outputs.
| Metric | Value |
|---|---|
Current Growth Rate | 9.2% |
Growth Uncertainty | ±14.6pp |
Observations | 13 |
Year 1 Projected | 7.9% |
Year 2 Projected | 6.8% |
Year 3 Projected | 6.0% |
Year 4 Projected | 5.3% |
Year 5 Projected | 4.7% |
what breaks the thesis
Overall Risk Rating: 6.5 / 10 (Premium valuation against slowing growth: P/B 2.18x, P/E 14.6x, EPS growth +1.4%) · # Key Risks: 8 (Ranked in the risk-reward matrix below) · Bear Case Downside: $240.00 (-18.1% vs current price of $306).
The non-obvious takeaway is that the thesis can break without a credit event. JPM still reports a strong 15.7% ROE , but that return is being capitalized at a premium 2.81x TBV and 14x earnings even though 2025 EPS grew only 1.4% and implied Q4 diluted EPS fell to $4.64 . That combination means the real risk is not solvency first; it is a de-rating from a premium starting point if investors conclude 2025 was near-peak earnings.
| Pillar | Invalidating Facts | P(Invalidation) |
|---|---|---|
earnings-power-rate-credit-cycle | JPM's ROTCE falls below a reasonable cost-of-equity range (roughly 11-12%) for at least 4 consecutive quarters excluding clearly one-time items.; Management guidance and reported results show normalized net interest income, fee revenue, and expense levels cannot restore ROTCE above cost of equity within the next 12-24 months.; Credit losses and reserve build demonstrate through-cycle underwriting economics are materially worse than assumed, with net charge-offs and provisions remaining elevated enough to keep returns below cost of equity even after rate normalization. | 28% True |
scale-moat-durability | JPM shows sustained share loss in core deposit, card, payments, or primary banking relationships for at least 4 quarters, indicating scale advantages are no longer protecting customer retention and acquisition.; Incremental competition forces structurally higher deposit pricing, marketing, or technology spend such that JPM's efficiency ratio and spread economics deteriorate without offsetting volume gains.; Peer banks or nonbanks match JPM's product breadth/distribution sufficiently to compress returns in multiple core businesses at once, proving the scale moat is no longer translating into superior profitability. | 24% True |
regulatory-capital-complexity-overhang | Regulatory capital requirements rise durably enough that JPM must operate with materially higher CET1 and cannot return excess capital at levels consistent with its historical payout framework.; A major regulatory, legal, compliance, or operational event results in recurring restrictions, large penalties, forced investment, or business limitations that durably reduce earnings power.; Management or regulators indicate complexity-related costs are structurally rising faster than revenue, and the burden lowers sustainable ROTCE and valuation multiples on a lasting basis. | 34% True |
diversification-vs-hidden-concentration | Segment disclosures show a majority of earnings and incremental profit growth are consistently coming from the most cyclical businesses, with other segments failing to offset downturns.; During a normal stress period, consumer banking and CIB weaken simultaneously and firmwide earnings volatility approaches that of more concentrated peers, demonstrating limited diversification benefit.; Cross-cycle results show wealth, payments, asset management, and other fee businesses are insufficient to stabilize returns when credit and capital-markets conditions deteriorate. | 31% True |
bank-native-valuation-mispricing | On updated assumptions for sustainable ROTCE, growth, and payout, JPM screens at or above fair value relative to its own history and high-quality bank peers on P/TBV and earnings-power frameworks.; Book value and tangible book value growth slow enough, or capital return falls enough, that forward shareholder yield plus compounding no longer supports excess returns from the current price.; The market rerates JPM upward to a valuation fully consistent with its sustainable profitability and risk, eliminating any discount implied by bank-native valuation methods. | 46% True |
ai-and-productivity-optionality | After 2-3 years of elevated AI/technology spending, JPM cannot show measurable improvement in headcount productivity, unit costs, cycle times, or revenue conversion attributable to these investments.; Technology and AI expenses continue rising but are absorbed by compliance, infrastructure, and competitive catch-up needs rather than creating operating leverage.; Management disclosures or segment results indicate AI-driven benefits are immaterial relative to JPM's cost base and therefore insufficient to affect consolidated margins or earnings growth. | 55% True |
Watch for drawdowns driven by fundamentals where funds de-risk faster than the business narrative updates.
fundamentals & operations
The non-obvious operating signal is deceleration, not deterioration. JPM still produced $182.45B of FY2025 revenue and a very high 31.3% net margin, but revenue growth slowed to +2.8% from about 12.3% in the prior year. That combination matters because the franchise is still converting scale into exceptional profit, yet the incremental growth rate now depends more on mix, capital return, and operating leverage than on broad-based expansion.
| Segment | Revenue | % of Total | Growth | Op Margin | ASP / Unit Economics |
|---|---|---|---|---|---|
Consumer & Community Banking | $76.03B | 41.67% | — | — | High-volume consumer banking/cards franchise; pricing and customer LTV —… |
Commercial & Investment Bank | ~$77.12B (derived from 42.27% share × $182.45B total) | 42.27% | — | — | Institutional wallet economics likely fee and spread driven, but not quantified in snapshot… |
Corporate / Nonsegment | ~$6.91B (derived from 3.79% share × $182.45B total) | 3.79% | — | — | Residual / treasury-like bucket; no unit economics disclosed… |
Remaining segments not broken out in snapshot… | ~$22.39B (residual) | 12.27% | — | — | Likely Commercial Banking + Asset & Wealth Management, but audited split not provided here… |
Total JPM | $182.45B | 100.00% | +2.8% | — | Scale economics visible in 31.3% net margin and 15.7% ROE… |
Core growth lever: the two large operating engines already account for 83.94% of revenue. If Consumer & Community Banking at $76.03B and Commercial & Investment Bank at about $77.12B merely grow at the company’s FY2025 rate of 2.8% through 2027, they would add roughly $8.70B of combined revenue, while total company revenue would rise by about $10.37B to roughly $192.82B ...
Top 3 Revenue Drivers
DriversJPM’s revenue base is dominated by two very large engines, with a smaller residual set of businesses providing diversification. Based on the provided snapshot, FY2025 revenue was $182.45B , and the best available mix evidence indicates that Commercial & Investment Bank represented 42.27% of revenue, while Consumer & Community Banking represented 41.67% , including $76.03B of revenue in CCB. Those two businesses alone therefore account for 83.94% of total revenue, which is the single most important structural fact in the operating model...
| Concentration Lens | Observable Disclosure | Read-Through | Risk |
|---|---|---|---|
Named single customer | No named customer revenue concentration disclosed | Large-bank reporting is organized by segment and balance-sheet exposure, not contract revenue by customer | Low direct evidence of single-client revenue dependency in the source snapshot |
Top 10 customer revenue | — | Not a decision-useful bank disclosure in this snapshot; concentration is better assessed by segment, counterparty, credit, and funding exposures | Low read-through for revenue concentration; disclosure gap remains |
Consumer franchise exposure | CCB = $76.03B, or 41.67% of FY2025 revenue | Diversified mass-market banking, card, and deposit relationships; risk is macro and credit sensitivity, not one-customer dependence | Medium segment concentration, low named-customer concentration |
Institutional franchise exposure | CIB is about $77.12B, or 42.27% of FY2025 revenue | Relationship-driven institutional engine; risk sits in capital-markets and client-activity cyclicality rather than disclosed contract duration | Medium segment concentration; named-client concentration is unavailable in the filings snapshot |
Overall assessment | The real concentration question is business-mix concentration: CCB and CIB together account for 83.94% of revenue | For JPM, concentration is better understood by segment and balance-sheet exposure than by named customers | Moderate segment concentration, low evidence of single-customer concentration |
| Region | Revenue | % of Total | Growth Rate | Currency Risk |
|---|---|---|---|---|
United States | — | — | — | Primary business likely USD-dominant, but not quantified… |
EMEA | — | — | — | FX and local regulatory risk present, but not quantified… |
Asia Pacific | — | — | — | FX and market-activity sensitivity not quantified… |
Latin America / Canada | — | — | — | FX and local credit-cycle exposure not quantified… |
Overall disclosure status | Geographic revenue split not provided in snapshot… | N/A | N/A | This limits precise currency and regional operating analysis… |
competitive position
Market Share: — (Source snapshot references market-share datasets but provides no percentages) · Direct Competitors: Multiple (Exact peer count —; market is clearly multi-firm rather than monopoly) · Moat Score: 7/10 (Scale, regulation, reputation, and switching frictions are meaningful but not fully quantified).
Most important takeaway. JPM's competitive edge looks more like a protected oligopoly position than a winner-take-all monopoly: the company earned $57.05B on $182.45B of 2025 revenue with $4.42T of assets, but revenue growth slowed to +2.8% and net income growth turned -2.4% . That combination says barriers are real and scale is monetized, yet incremental pricing power is not strong enough to assume permanently rising margins without mean reversion risk.
| Metric | JPM | Competitor 1 | Competitor 2 | Competitor 3 |
|---|---|---|---|---|
Revenue | $182.45B Leader in disclosed data | — | — | — |
Revenue Growth | +2.8% | — | — | — |
Gross Margin | Not meaningful / — for bank reporting… | — | — | — |
Op Margin | — | — | — | — |
Net Margin | 31.3% Leader in disclosed data | — | — | — |
R&D / Revenue | — | — | — | — |
Takeaway. The missing peer rows are themselves informative: the source snapshot is strong enough to prove JPM's enormous scale, but not strong enough to prove a quantified spread over named rivals. That pushes the moat conclusion toward semi-contestable oligopoly rather than unquestioned dominance.
| Metric | Value |
|---|---|
Total assets | $4.42T |
Shareholders' equity | $362.44B |
Revenue | $182.45B |
Net income | $57.05B |
Greenwald Step 1: Contestability Assessment
SEMI-CONTESTABLEUsing Greenwald's framework, this market is best classified as semi-contestable : new entry is difficult, but the economically relevant rivalry is among a small number of already-scaled incumbents rather than between JPM and greenfield entrants. The evidence for high entry barriers is straightforward from the source snapshot. JPM ended 2025 with $4.42T of total assets, $362.44B of equity, and generated $182.45B of revenue with $57.05B of net income...
| Mechanism | Relevance | Strength | Evidence | Durability |
|---|---|---|---|---|
Habit Formation | Relevant | Moderate | Banking is recurring and embedded in payroll, bill pay, card use, and savings behavior, but no churn metric is disclosed… | Multi-year if accounts are primary |
Switching Costs | Highly relevant | Moderate | Changing primary bank often requires account transfer, autopay changes, documentation, and possible re-underwriting; affluent tiers also use relationship bundles. Supporting evidence cite Chase Private Client at $150K minimum and J.P. Morgan Private Client at $750K minimum… | Multi-year; strongest in wealth and treasury relationships… |
Brand as Reputation | Highly relevant | Strong | For deposits, lending, custody, and advice, trust matters. JPM's 2025 scale of $4.42T assets and $57.05B net income supports reputation and perceived safety… | Long duration while balance-sheet strength persists… |
Network Effects | Partly relevant | Weak | Banking has some ecosystem effects in payments and treasury relationships, but the snapshot provides no direct platform-network metrics… | Limited unless linked to payments rails or merchant acceptance… |
Search Costs | Highly relevant | Moderate | Products are complex, fee structures vary, and relationship products require comparison across rates, service, and trust. Snapshot lacks formal survey data but complexity is evident in full-service banking… | Ongoing, especially for businesses and affluent households… |
Overall Captivity Strength | Weighted assessment | Moderate | Captivity is strongest in trust, complexity, and relationship switching, but lacks disclosed retention or wallet-share metrics… | Durable but not impregnable |
See detailed supplier-power analysis in the Supply Chain / valuation-linked tab.
market size & tam
TAM: $4.56T (Practical balance-sheet TAM proxy based on peak total assets at 2025-09-30; year-end assets were $4.42T.) · SAM: $4.42T (Current served asset base at 2025-12-31; this is the best disclosed proxy for JPM's active serviceable market.) · SOM: $182.45B (2025 revenue monetized from the served base, with 31.3% net margin and $57.05B net income.).
Takeaway. JPM's practical TAM is already enormous, but the more important point is that growth is maturing faster than scale is expanding. Revenue rose to $182.45B in 2025 and assets ended at $4.42T , yet annual revenue growth slowed sharply to +2.8% from +12.3% the prior year, implying near-term upside depends more on deeper monetization of an existing franchise than on opening materially new end markets.
| Segment / Proxy | Current Size | 2028 Projected | CAGR / Growth Assumption | Company Share |
|---|---|---|---|---|
Consolidated revenue pool | $182.45B | $198.21B | 2.8% annualized, using 2025 reported revenue growth as the forward run-rate… | 100% of JPM reported revenue base |
Balance-sheet capacity proxy | $4.42T year-end assets; $4.56T peak assets in Q3 2025… | $5.96T | 10.5% annualized, using 2025 asset growth vs. 2024 year-end… | 100% of JPM reported asset base |
Equity capital base | $362.44B | $420.78B | 5.1% annualized, using 2025 equity growth vs. 2024… | 100% of JPM reported equity base |
Earnings monetization pool | $57.05B net income | $61.98B | 2.8% annualized, held in line with 2025 revenue growth due to limited segment disclosure… | 100% of JPM reported earnings base |
Per-share revenue capture | $67.67 revenue per share | $73.52 | 2.8% annualized, using revenue growth as the proxy… | Per-share participation improved as shares fell from 2.80B to 2.70B… |
Business-line TAM segmentation | — | — | — | Consumer, commercial, investment banking, markets, and wealth shares are — in the provided snapshot… |
Bottom-up TAM methodology: franchise-scale proxies, not industry hype
BOTTOM-UPBecause the source snapshot does not disclose an external industry TAM for JPM, the most defensible bottom-up method is to size the market from what the bank is already demonstrably serving . The core building blocks are reported scale metrics from available filings: $182.45B of 2025 revenue, $4.42T of year-end assets, $4.56T of peak Q3 2025 assets, and $362.44B of equity. For a universal bank, those figures are more informative than generic banking-industry claims because they reflect the actual balance-sheet and capital capacity through which demand can be monetized...
Penetration, maturity, and runway
PENETRATIONJPM's penetration of its practical market looks deep rather than early-stage . On the available data, JPM already operates with $4.42T of assets, $4.06T of liabilities, and $362.44B of equity, which suggests the main constraint on further market capture is not lead generation or customer awareness, but capital intensity, funding capacity, and regulation. In other words, the bank is not trying to prove product-market fit; it is optimizing a mature, multi-product franchise...
Biggest caution. The market looks huge because assets reached $4.56T at the Q3 2025 peak, but monetization is clearly slowing: revenue growth fell to +2.8% in 2025 from +12.3% in 2024. That combination raises the risk that incremental balance-sheet growth is entering a lower-return, more capital-constrained phase rather than signaling a fresh step-up in real TAM.
TAM Sensitivity
| input | value |
|---|---|
| id | calc-jpm-tam |
| formula | sensitivity |
| output layout | dark_panel |
| base tam | 4560000000000.0 |
product & technology
R&D Spend ($): — (No R&D expense line in available filings/source snapshot) · R&D % Revenue: — (Cannot compute without disclosed R&D expense; 2025 revenue was $182.45B) · Products/Services Count: 5 core franchises (Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, Asset & Wealth Management, and enterprise technology/control stack assessed from available filings context).
Most important takeaway. JPM's product-and-technology edge is best understood through funding capacity rather than disclosed innovation spend . The company generated $182.45B of revenue and $57.05B of net income in 2025 while still posting a 31.3% net margin , which implies management can keep investing in platforms, cybersecurity, and data infrastructure even though direct R&D and technology-expense lines are — in the available filings.
| Product / Service Family | Revenue Contribution ($) | % of Total | Growth Rate | Lifecycle Stage | Competitive Position |
|---|---|---|---|---|---|
Consumer & Community Banking | — | — | — | MATURE | Leader |
Corporate & Investment Bank | — | — | — | MATURE | Leader |
Commercial Banking | — | — | — | MATURE | Leader |
Asset & Wealth Management | — | — | — | GROWTH | Challenger |
Enterprise Payments / Treasury / Data & Risk Infrastructure… | — | — | — | GROWTH | Leader |
Bank-wide digital servicing, fraud, control, and cloud/data modernization… | Not separately monetized or disclosed | — | — | GROWTH | Leader in scale, not directly measurable from snapshot… |
Takeaway. The portfolio is unquestionably broad, but segment-level revenue by product is — in this snapshot . For investors, that means the more reliable signal is enterprise earning power and balance-sheet support, not management's product taxonomy.
Technology stack: scale and control are the moat
PLATFORMJPM's core technology differentiation is not well captured by a single patented product; it is better framed as a deeply integrated bank operating stack spanning payments, client servicing, risk controls, balance-sheet management, fraud mitigation, and data infrastructure. The available filings do not disclose technology spend, cloud mix, AI deployment, or digital-user KPIs, so the moat must be inferred from the economic outcomes visible in the SEC EDGAR data. Those outcomes remain strong: 2025 revenue was $182.45B , net income was $57.05B , net margin was 31.3% , and ROE was 15.7% ...
R&D pipeline: funded internally, but milestones are —
PIPELINEThe source snapshot does not disclose a formal R&D expense line, technology roadmap, launch calendar, or named product pipeline . That means a classic product-launch timeline cannot be built from the available filings. Still, the financial base is strong enough to support an ongoing modernization program...
IP and moat assessment: execution, data, licenses, and trust outweigh disclosed patents
MOATJPM's defensibility appears to come more from institutional scale, embedded customer relationships, regulatory infrastructure, risk models, operating data, and brand trust than from disclosed patents. The source snapshot does not provide a patent count, trade-secret inventory, or estimated legal protection period, so a narrow patent-led moat analysis would overstate what is actually observable. Instead, the filings point toward a system-level moat: the bank produced $182.45B of revenue , $57.05B of net income , and ended 2025 with $4.42T of total assets and $362.44B of equity ...
supply chain
Key Supplier Count: — (No vendor list or critical third-party count is provided in the source snapshot.) · Single-Source %: — (Supplier-level concentration is —; the key dependency is funding/liquidity rather than physical sourcing.) · Customer Concentration: — (Top-10 customer % of revenue is not provided in the available filings snapshot.).
Important takeaway. For JPM, “supply chain” risk is really a funding-and-infrastructure dependency question, not a physical procurement issue. The clearest evidence is the combination of $4.06T of liabilities against $4.42T of assets at 2025-12-31 and -$147.782B of computed operating cash flow, which means resilience depends more on uninterrupted funding channels, counterparties, and core platforms than on any disclosed raw-material supplier.
| Supplier | Component/Service | Revenue Dependency (%) | Substitution Difficulty (Low/Med/High) | Risk Level (Low/Med/High/Critical) | Signal (Bullish/Neutral/Bearish) |
|---|---|---|---|---|---|
Funding markets / wholesale funding channels… | Balance-sheet funding and liquidity continuity… | —; balance-sheet proxy shows liabilities at 91.9% of assets… | HIGH | CRITICAL | BEARISH |
Customer deposit base | Primary operating funding source | — | HIGH | HIGH | NEUTRAL |
Core payments and settlement infrastructure… | Transaction processing and settlement | — | HIGH | HIGH | NEUTRAL |
Core banking / cloud / data-center vendors… | Platform uptime and system availability | — | HIGH | HIGH | NEUTRAL |
Market data and trading connectivity vendors… | Markets pricing, execution, and risk management inputs… | — | HIGH | MEDIUM | NEUTRAL |
Telecom and network providers | Branch, office, and digital connectivity… | — | MEDIUM | MEDIUM | NEUTRAL |
| Relationship / Exposure Bucket | Observable Share / Disclosure | Relationship Structure | Primary Concentration Risk | Trend |
|---|---|---|---|---|
Named single customer | No named customer dependence disclosed | Banking franchise, not contract manufacturing; relationships are recurring and are not presented as fixed customer contracts | Low direct customer concentration risk in the source snapshot | STABLE |
Consumer & Community Banking | $76.03B, or 41.67% of FY2025 revenue | High-volume consumer banking, card, and deposit relationships | Consumer credit and spending slowdown, not contract renewal risk | STABLE |
Commercial & Investment Bank | About $77.12B, or 42.27% of FY2025 revenue | Relationship-led institutional and capital-markets activity | Capital-markets, advisory, and corporate-activity cyclicality | STABLE |
Residual businesses / diversification | Roughly 16.06% of revenue sits outside CCB and CIB | Asset & wealth, corporate / other, and residual businesses diversify the franchise | Smaller individually, but disclosure in this snapshot is less granular | STABLE |
Overall read-through | Customer concentration looks low; segment concentration is the more relevant lens | The franchise is diversified by relationship count, but still concentrated in two giant operating engines | Funding, liquidity, and business-mix concentration matter more than any single disclosed client | STABLE |
Funding Chain, Not Physical Inputs, Is the Real Concentration Risk
CONCENTRATIONJPM does not disclose a traditional manufacturing-style supplier roster in the available filings snapshot, so the most decision-useful way to read “supply concentration” is through the bank’s dependence on funding, operating infrastructure, and transaction networks. The hard numbers point to a franchise whose continuity depends on scale and access rather than on parts inventory. At 2025-12-31, total assets were $4.42T and total liabilities were $4.06T , which means roughly 91.9% of the balance sheet was liability-funded on a simple assets-to-liabilities proxy...
Geographic Exposure Is Undisclosed, So Complexity Must Be Inferred Indirectly
GEOGRAPHYThe available filings snapshot does not disclose a regional sourcing map, manufacturing footprint, or supplier-country concentration for JPM, so a conventional geographic supply-chain analysis cannot be completed directly. That is an important limitation. There is no confirmed percentage of services sourced from the U.S., Europe, Asia, or any other region, and there is also no disclosed tariff exposure...
| Component | % of COGS | Trend | Key Risk |
|---|---|---|---|
Liability-funded balance sheet (proxy) | 91.9% of assets | Rising vs 91.5% in 2024 | High dependence on stable funding and liquidity channels… |
Equity support (proxy) | 8.2% of assets | Stable to slightly lower vs 8.6% in 2024… | Thin equity share relative to balance-sheet scale increases sensitivity in stress… |
Goodwill / acquired intangible burden (proxy) | 1.2% of assets | STABLE | Low current integration risk; major acquisition-driven disruption not evident… |
Stock-based compensation | 2.0% of revenue | — for prior year in snapshot… | Talent retention and compensation inflation in key control functions… |
Net margin retention | 31.3% of revenue | Down implied by -2.4% net income growth vs +2.8% revenue growth… | Earnings conversion did not fully keep pace with revenue growth… |
Operating cash flow conversion | -81.0% of revenue | Negative | Cash-flow profile raises dependence on external funding flexibility… |
catalyst map
Total Catalysts: 10 (8 operating/regulatory; 2 speculative product/partnership items) · Next Event Date: 2026-04-14 (Q1 2026 earnings date is not fully corroborated in the source snapshot, not company-confirmed here) · Net Catalyst Score: +2 (Modestly bullish: capital return and per-share accretion outweigh NII compression risk).
Most important takeaway. The key catalyst is not simple revenue growth; it is per-share earnings accretion from capital deployment. In 2025, net income fell 2.4% year over year while diluted EPS still rose 1.4% to $20.02 , and shares outstanding dropped from 2.80B to 2.70B ...
| Date | Event | Category | Impact | Probability (%) | Directional Signal | |
|---|---|---|---|---|---|---|
2026-04-14 | Q1 2026 earnings release; date is scheduled in the source snapshot but not otherwise confirmed here… | Earnings | HIGH | 85% | Neutral to Bullish NEUTRAL/BULL | |
Q2 2026 (date —) | Management commentary on whether NII ex Markets improves from the prior disclosed decline of $185M, or 1% | Earnings | HIGH | 80% | Bullish if stabilized; Bearish if worse TWO-SIDED | |
Q2 2026 (date —) | Regulatory capital and repurchase-capacity update; catalyst path supported by the July 1, 2025 capital update evidence… | Regulatory | HIGH | 70% | BULLISH | |
Q2 2026 | Rate-path and deposit repricing effects on spread income and funding pressure… | Macro | MEDIUM | 100% | NEUTRAL | NEUTRAL |
Q3 2026 earnings window (date —) | Q2 2026 earnings release and updated normalized earnings commentary… | Earnings | HIGH | 80% | NEUTRAL | NEUTRAL |
Q3 2026 (date —) | Third-quarter dividend and common share repurchase program confirmation, analogous to the July 1, 2025 update… | Regulatory | HIGH | 70% | BULLISH |
| Date/Quarter | Event | Category | Expected Impact | Bull/Bear Outcome |
|---|---|---|---|---|
2026-04-14 | Q1 2026 earnings | Earnings | HIGH | Bull: EPS and net income stay near or above 2025 quarterly run-rate; Bear: earnings slip enough to challenge premium multiple… |
Q2 2026 | NII ex Markets trend check | Earnings | HIGH | Bull: prior -1% pressure flattens or improves; Bear: deposit margin compression persists and offsets scale benefits… |
Q2 2026 (2) | Capital return and regulatory flexibility update… | Regulatory | HIGH | Bull: continued repurchases reinforce EPS accretion; Bear: tighter capital requirements slow buybacks… |
Q2-Q3 2026 | Macro rate path and funding-cost reset | Macro | MEDIUM | Bull: lower funding pressure and stronger markets activity; Bear: spread compression worsens faster than fee offset… |
Q3 2026 | Q2 2026 earnings and outlook refresh | Earnings | HIGH | Bull: management shows normalized earnings durability without one-time items; Bear: growth remains asset-heavy but margin-light… |
Q3 2026 (2) | Dividend/repurchase program confirmation… | Regulatory | HIGH | Bull: another year of share count reduction similar to 2025 path; Bear: slower capital return weakens per-share thesis… |
Quarterly Outlook: What to Watch in the Next 1-2 Quarters
NEAR TERMThe near-term setup is about whether JPM can preserve its premium return profile while absorbing rate and funding pressure. The most useful baseline from the available filings is the consistency of 2025 quarterly earnings: net income of $14.64B, $14.99B, and $14.39B in Q1-Q3 2025, with diluted EPS of $5.07, $5.24, and $5.07 . For the next one to two quarters, I would treat EPS at or above roughly $5.10 and quarterly net income at or above $14.5B as constructive signals that normalized earnings remain intact...
| Date | Quarter | Consensus EPS | Consensus Revenue | Key Watch Items |
|---|---|---|---|---|
2026-04-14 | Q1 2026 | — | — | Whether quarterly EPS holds near the 2025 range of $5.07-$5.24; any update on NII ex Markets and capital return… |
Q3 2026 window (date —) | Q2 2026 | — | — | Whether management shows stabilization after the prior disclosed $185M, or 1%, NII ex Markets decline… |
Q4 2026 window (date —) | Q3 2026 | — | — | Repurchase pace, dividend commentary, and evidence that fee businesses are carrying more of the growth mix… |
Q1 2027 window (date —) | Q4 2026 / FY2026 | — | — | Annual earnings durability, share count trend versus 2.70B current level, and 2027 capital-return setup… |
street expectations
Moderate Buy consensus (15 buy, 15 hold, 0 sell) with average target ~$337 (range $295–$391). Key targets: Goldman $361, UBS $375, Evercore $340, Piper Sandler $345. FY26 EPS consensus ~$22.42 (+10.2%).
Key takeaway. The most important point is that JPM’s valuation appears to be supported more by durability than by growth acceleration. Audited FY2025 revenue increased only +2.8% to $182.45B and net income declined -2.4% to $57.05B , yet the stock still trades at 14x earnings and 2.81x TBV ; that combination implies the market is underwriting sustained returns, not a reacceleration story.
$340
12-month target aligned with analyst consensus (~$337)
$250
That puts the shares about 11.9% below our…
| Metric | Street Consensus | Our Estimate | Diff % | Key Driver of Difference |
|---|---|---|---|---|
Q1 2026 EPS | — | $4.90 | Not computable | Assumes stabilization above implied Q4 2025 EPS of $4.64 but below Q2 2025 peak of $5.24… |
FY2026 Revenue | — | $187.92B | Not computable | Assumes 3.0% growth from FY2025 revenue of $182.45B as franchise momentum persists without reacceleration… |
FY2026 Diluted EPS | — | $20.50 | Not computable | Assumes modest earnings growth supported by stable margins and share count discipline near 2.70B… |
FY2026 Net Margin | — | 31.0% | Not computable | Assumes profitability remains close to reported 31.3% rather than reverting sharply lower… |
Fair Value / Target Price | — | $330 | Not computable | DCF based on 10.1% dynamic WACC and sustained franchise returns… |
| Year | Revenue Est | EPS Est | Growth % |
|---|---|---|---|
2023A | $158.10B | — | — |
2024A | $177.56B | — | +12.3% revenue |
2025A | $182.45B | $20.02 | +2.8% revenue / +1.4% EPS |
2026E | $187.92B | $20.50 | +3.0% revenue / +2.4% EPS |
2027E | $194.50B | $21.30 | +3.5% revenue / +3.9% EPS |
| Metric | Value |
|---|---|
Revenue growth | +2.8% |
Net income | -2.4% |
Net income (2) | +1.4% |
EPS | $20.02 |
EPS (2) | $5.07 |
EPS (3) | $5.24 |
Fair Value | $4.64 |
ROE near | 15.7% |
Revision Trend Read-Through
SPARSE DIRECT DATADirect analyst revision history, formal upgrades, downgrades, and target changes are — . That means we cannot credibly publish a sell-side revision tape for JPM without inventing data, which would be inappropriate. Instead, the cleanest way to interpret likely estimate direction is through the progression of the reported operating numbers in the FY2025 10-K and 2025 quarterly filings...
earnings scorecard
Beat Rate: 1/1 quarters (Only one quarter in the snapshot includes a disclosed consensus EPS comparison: Q4 2025 adjusted EPS beat) · Avg EPS Surprise: +6.1% (Q4 2025 adjusted EPS of $5.23 vs $4.93 consensus in source evidence) · TTM EPS: $20.02 (FY2025 diluted EPS from available filings).
| Period | EPS | YoY Change | Sequential |
|---|---|---|---|
2022-06 | $2.76 | ||
2022-09 | $3.12 | +13.0% | |
2023-03 | $4.10 | +31.4% | |
2023-06 | $4.75 | +15.9% | |
2023-09 | $4.33 | +27.8% | -8.8% |
2024-03 | $4.44 | +42.3% | +2.5% |
Important takeaway. JPM’s headline earnings look stronger than the quarter-by-quarter cadence underneath them. Full-year diluted EPS was $20.02 , but the 2025 quarterly sequence was $5.07, $5.24, $5.07, and an implied $4.64 , showing that earnings softened into year-end even as management still pointed to $103B of 2026 NII...
| Quarter / Period | Guidance Range | Actual | Within Range (Y/N) | Error % |
|---|---|---|---|---|
Q1 2025 | — | — | N/A na | Not calculable |
Q2 2025 | — | — | N/A na | Not calculable |
Q3 2025 | — | — | N/A na | Not calculable |
Q4 2025 | — | — | N/A na | Not calculable |
FY2025 NII (after Q2 update) | About $95.5B | — | Pending confirmation na | Not calculable |
FY2026 NII | $103B | Pending period | Pending na | N/A |
| Metric | Value |
|---|---|
Revenue | $182.45B |
Revenue (2) | $57.05B |
Net income | $20.02 |
EPS | 31.3% |
EPS (2) | 15.7% |
EPS (3) | $5.07 |
EPS (4) | $5.24 |
Fair Value | $4.64 |
Earnings Quality: Strong franchise earnings, but Q4 quality was less clean than the headline beat
QUALITY: GOOD WITH CAVEATUsing the available filings, JPM’s earnings quality still screens as strong at the annual level. FY2025 revenue was $182.45B , net income was $57.05B , diluted EPS was $20.02 , net margin was 31.3% , and ROE was 15.7% . Those are not numbers produced by accounting noise alone; they reflect a bank still generating elite profitability at scale...
Revision Trends: Management raised NII, but external estimate transparency is limited
REVISIONS: MODESTLY POSITIVEThe source snapshot does not include a full 90-day analyst revision feed, so the cleanest revision signal comes from management rather than the Street. After Q2 2025, JPM raised its FY2025 NII outlook to about $95.5B from nearly $94.5B . That is a meaningful directional data point because large-bank estimate revisions usually start with the net interest income line, not with a sudden change in fee income assumptions...
alternative data
Overall Signal Score: 58/100 (Neutral; conviction 58/100. DCF fair value $330 vs price $306 implies 11.9% upside, offset by slower growth and model conflict.) · Bullish Signals: 5 (Strong absolute profitability, ROE 15.7%, share count down to 2.70B, book value support, DCF above market.) · Bearish Signals: 4 (Revenue growth slowed to 2.8%, net income growth -2.4%, implied Q4 EPS fell to $4.64, liabilities/equity 11.21x.).
Most important takeaway. The non-obvious signal is that per-share resilience is stronger than underlying profit momentum . Diluted EPS increased to $20.02 in 2025 and the deterministic ratio shows +1.4% EPS growth, but net income growth was -2.4% and shares outstanding fell from 2.80B to 2.70B ...
| Category | Signal | Reading | Trend | Implication |
|---|---|---|---|---|
Operating momentum | Revenue growth decelerated | Revenue rose from $177.56B in 2024 to $182.45B in 2025; Revenue Growth YoY +2.8% | Slowing | Still growing, but the pace is now consistent with maturity rather than reacceleration. |
Profitability | Absolute earnings remain very strong | 2025 net income $57.05B; net margin 31.3%; ROE 15.7%; ROA 1.3% | Stable-to-softening | Core earnings power remains high enough to support a premium multiple if durability holds. |
Per-share support | Buybacks cushioned EPS | Diluted EPS $20.02; EPS Growth YoY +1.4%; shares outstanding fell from 2.80B to 2.70B… | Supportive | EPS optics are better than profit growth, which helps sentiment but can mask slower business momentum. |
Quarterly earnings | Late-year moderation | 2025 net income: Q1 $14.64B, Q2 $14.99B, Q3 $14.39B, implied Q4 $13.03B; diluted EPS: $5.07, $5.24, $5.07, implied $4.64… | Weakening | Direction into year-end was softer; investors may anchor on the lower implied Q4 run-rate. |
Balance sheet | Asset growth outpaced equity growth | Total assets increased from $4.00T to $4.42T; shareholders' equity increased from $344.76B to $362.44B… | Expansionary | Higher earning-asset capacity is positive, but balance-sheet expansion raises sensitivity to funding and credit conditions. |
Leverage/capital | Highly levered by design | Total liabilities $4.06T; Total Liab/Equity 11.21; Debt/Equity 0.74… | Elevated | Strong profitability offsets leverage today, but this remains the key structural sensitivity. |
| Metric | Value |
|---|---|
Fair Value | $306 |
Price-to-book | 18x |
2024 total assets | $4.00T |
2025 total assets | $4.42T |
Alternative Data Read-Through: Sparse External Signal Set
LIMITED COVERAGEThe source snapshot does not disclose confirmed alternative-data series for JPM such as job postings, web traffic, app downloads, patent filings, social-media traffic, or developer ecosystem metrics. That limitation matters because banks often show early operating changes in consumer engagement, hiring intensity, or digital-product momentum before they appear in annual revenue...
| Metric | Value |
|---|---|
Market cap | $306 |
Market capitalization | $810B |
Market capitalization (2) | 14.6x |
Market capitalization (3) | 18x |
DCF | 11.9% |
DCF (2) | $330 |
EPS | $20.02 |
EPS (2) | $5.24 |
Sentiment Indicators: Market Confidence Is Positive, But Not Euphoric
MIXEDThe snapshot does not include direct retail or institutional sentiment datasets such as options skew, short interest, fund flows, analyst-revision breadth, or social-media sentiment. As a result, sentiment has to be inferred only from the market and valuation data that are actually present. On that basis, the stock’s $306 price, $810B market capitalization, 14.6x P/E, and 2.18x price-to-book all suggest investors are willing to pay a premium for durability and franchise quality...
historical analogies
JPMorgan Chase currently screens less like a turnaround bank and more like a mature, premium franchise entering a later-cycle normalization phase. The audited record shows a bank still growing from enormous scale, revenue rose from $158.10B in 2023 to $177.56B in 2024 and $182.45B in 2025, but the pattern underneath that growth matters more than the headline. Net income growth turned negative at -2.4% while diluted EPS still increased +1.4% to $20.02, implying that capital return and franchise quality are doing more of the work than operating acceleration. Historically, that setup tends to resemble the best periods of large universal banks: premium valuation can persist, but upside becomes more dependent on sustaining returns and buybacks than on raw balance-sheet expansion.
Takeaway. The non-obvious point is that JPM's per-share resilience is stronger than its aggregate earnings trend: 2025 net income growth was -2.4% , but diluted EPS still grew +1.4% to $20.02 . That divergence lines up with the decline in shares outstanding from 2.80B at 2024 year-end to 2.70B at 2025 year-end, which means the current historical analog is a capital-return compounder rather than a bank enjoying broad-based operating acceleration.
| Analog Company | Era/Event | The Parallel | What Happened Next | Implication for This Company |
|---|---|---|---|---|
JPMorgan itself | 2024-2025 balance-sheet expansion and earnings normalization… | Assets grew from $4.00T at 2024 year-end to a $4.56T peak in 3Q25 before ending 2025 at $4.42T, while revenue still rose to $182.45B. | The pattern suggests a dominant funding and client franchise absorbing flows, but with late-year earnings cooling as implied 4Q25 net income fell to $13.03B. | This is a premium-franchise, late-cycle analog. The key question is not survival, but whether more assets convert into sustained returns or simply a larger balance sheet. |
Morgan Stanley | Mature premium-bank phase | Useful analog for a large financial institution that wins a higher multiple because investors trust business mix and capital return more than raw revenue growth. | Historically, premium reratings became steadier but less explosive once the market already priced in quality; future stock moves depended on maintaining return metrics rather than narrating reinvention. | JPM at 14.6x P/E and 2.81x TBV looks similar in market psychology: upside likely comes from holding a premium, not from a sudden multiple step-change. |
Goldman Sachs | Late-cycle earnings plateau at a high-quality franchise… | A top-tier financial institution can still trade well even when revenue grows but incremental earnings momentum softens. | When quarterly cadence loses momentum, investors typically stop paying for acceleration and instead value the company on normalized earnings power. | JPM's annual diluted EPS of $20.02 implies 4Q25 diluted EPS of $4.64, below the first three quarters, so the stock may behave more like a quality compounder than a momentum trade. |
Bank of America | Post-repair capital-return compounding | Once a large bank is no longer in repair mode, share count reduction can matter as much as underlying profit growth for per-share value creation. | In that pattern, book value growth and repurchases often drive investor returns more reliably than headline top-line acceleration. | JPM's share count fell from 2.80B to 2.70B, so the relevant analog is a scaled bank using excess capital to preserve EPS growth even if net income softens. |
Wells Fargo | Premium multiple vulnerable to growth deceleration… | Large banks can keep premium valuations only as long as investors believe returns are durable and regulation or normalization will not erode earnings quality. | Once earnings momentum fades, the valuation premium can compress even if the franchise remains profitable and systemically important. | JPM's 15.7% ROE justifies a premium today, but the implied 4Q25 slowdown and already-full 2.81x TBV mean the analog warns against assuming endless multiple expansion. |
Lesson from the Morgan Stanley-style premium-compounder analog. When a financial franchise is already viewed as best-in-class, the stock usually rises through steady earnings durability and capital return, not through a dramatic narrative rerating...
| Metric | Value |
|---|---|
Revenue FY2025 | $182.45B |
Revenue FY2024 | $177.56B |
Revenue FY2023 | $158.10B |
Revenue growth FY2025 | +2.8% |
Net income growth FY2025 | -2.4% |
Q1 2025 net income | $14.64B |
Q2 2025 net income | $14.99B |
Q3 2025 net income | $14.39B |
JPM Looks Like a Mature Franchise in Late-Cycle Normalization
MATURITYBased on the available filings, JPM is best classified in the Maturity phase rather than Early Growth, Turnaround, or Decline. The 2025 10-K shows revenue of $182.45B , up from $177.56B in 2024 and $158.10B in 2023, so the franchise is still expanding from a very large base. But the quality of growth matters: computed revenue growth was +2.8% in 2025, while net income growth was -2.4% ...
| Metric | Value |
|---|---|
Goodwill 1Q25 | $52.62B |
Goodwill 2Q25 | $52.75B |
Goodwill 3Q25 | $52.72B |
Goodwill FY2025 | $52.73B |
Net income growth FY2025 | -2.4% |
EPS growth FY2025 | +1.4% |
Diluted EPS FY2025 | $20.02 |
Total assets FY2024 | $4.00T |
management & leadership
Management Score: 4.0 / 5.0 (Average of 6-dimension scorecard based on 2025 operating, balance-sheet, and capital-allocation evidence) · Insider Ownership %: — (No authoritative ownership table or Form 4 summary is included in the provided snapshot) · Leadership Continuity / Tenure: CEO continuity; board refresh in 2025 (James Dimon as Chairman & CEO per company disclosures; Brad D. Smith joined the board effective 2025-01-21; Michele G. Buck elected to the board effective 2025-03-17 per JPMorgan Chase IR).
Most important takeaway. The strongest management signal is capital allocation discipline, not biography: shares outstanding fell from 2.80B at 2024-12-31 to 2.70B at 2025-12-31 even as shareholders' equity increased from $344.76B to $362.44B . That combination helped support +1.4% EPS growth to $20.02 despite -2.4% net income growth , which is unusually strong evidence that management is protecting per-share value rather than merely growing the balance sheet.
Dimon-led team still appears to be building scale advantages, but succession remains the swing factor
ASSESSMENTOn the numbers available from SEC EDGAR and the supplied analytical findings, JPMorgan's leadership team continues to look like a net builder of competitive advantage rather than a steward of decline. The operating record is the clearest evidence. Revenue increased from $158.10B in 2023 to $177.56B in 2024 and then to $182.45B in 2025 , while 2025 net income still reached $57.05B ...
| Name | Title / Role | Tenure / Date | Background / Status | Key Achievement or Observation |
|---|---|---|---|---|
James Dimon | Chairman and Chief Executive Officer | Current tenure —… | Role identified in the supplied leadership evidence rather than a verified officer table in this dataset… | Leadership period covered by 2025 results: revenue $182.45B, net income $57.05B, diluted EPS $20.02… |
Brad D. Smith | Director | Effective 2025-01-21 | Board refresh addition confirmed in the analytical findings… | Joined during a year in which assets ended at $4.42T and equity rose to $362.44B… |
Michele G. Buck | Director | Serving since 2025 | Newer board member confirmed in the analytical findings… | Part of 2025 board refresh at a company with $810B market capitalization as of 2026-05-28… |
Chief Financial Officer | — | — | No authoritative executive roster or tenure table is included in the provided source set… | Limits direct assessment of finance-lead continuity and capital-markets execution… |
Chief Operating Officer / President | — | — | No verified officer-level disclosure is included in the provided source set… | Creates a disclosure gap around succession depth below the CEO-chair level… |
Governance is credible on continuity and refresh, but oversight concentration is still real
GOVERNANCEThe governance picture in the provided materials is constructive, but not fully transparent. The strongest confirmed datapoints are that the board has 11 members , Brad D. Smith joined effective January 21, 2025 , and Michele G...
| Metric | Value |
|---|---|
Reported 2025 CEO pay package of | $43M |
Key Ratio | 10.3% |
Revenue | $182.45B |
Net income | $57.05B |
EPS | $20.02 |
ROE | 15.7% |
2024 equity | $344.76B |
2025 equity | $362.44B |
Compensation appears directionally aligned with performance, but official proxy detail is missing here
PAYThe available evidence suggests compensation is at least directionally aligned with shareholder outcomes, but this is one area where the source set is incomplete. The analytical findings cite a reported 2025 CEO pay package of $43M , up 10.3% , though that figure is explicitly described as coming from third-party compensation evidence rather than the official SEC proxy tables in this snapshot. That distinction matters...
macro sensitivity
Rate Sensitivity: High ($4.42T assets vs $362.44B equity; total liabilities/equity 11.21) · FX Exposure: — (No geographic revenue mix in the available filings snapshot) · Commodity Exposure: Low direct (Industry is National Commercial Banks; no COGS commodity inputs disclosed).
Takeaway. The non-obvious point is how small macro changes can become very large in dollar terms for JPM because of balance-sheet scale, not because current profitability is weak. With $4.42T of assets at 2025 year-end and ROA of 1.3% , even modest rate, spread, or credit shifts can move earnings materially...
Interest-Rate Sensitivity Is the Primary Macro Variable
RATESJPM’s macro sensitivity is dominated by rates, funding costs, and credit spreads rather than classic industrial inputs. The available filings show a year-end 2025 balance sheet of $4.42T of assets , $4.06T of liabilities , and $362.44B of equity , which makes valuation and earnings highly sensitive to small changes in spread economics. The clearest operating clue is deceleration: revenue rose from $177.56B in 2024 to $182.45B in 2025, only +2.8% , while quarterly earnings softened to an implied $13.03B in Q4 2025 from $14.99B in Q2 2025...
| Region / Lens | Revenue % from Region | Primary Currency | Hedging Strategy | Net Unhedged Exposure | Impact of 10% Move |
|---|---|---|---|---|---|
Consolidated reported revenue | 100% reported in USD | USD | Reporting currency only; economic hedging —… | — | Translation impact cannot be isolated from snapshot… |
United States | — | USD | — | — | Direct transaction FX impact not quantified… |
Europe | — | EUR/GBP/other — | — | — | Cannot quantify from available filings snapshot… |
Asia-Pacific | — | Local currencies — | — | — | Cannot quantify from available filings snapshot… |
Latin America / Emerging Markets | — | Local currencies — | — | — | Cannot quantify from available filings snapshot… |
Other / Corporate-level translational exposure… | — | Multiple / — | Natural or financial hedging —… | Not quantifiable | Use caution; disclosure gap prevents precise P&L estimate… |
Takeaway. FX is clearly a real operating topic for a global bank, but this snapshot does not disclose the geographic revenue split, hedging program, or net unhedged exposure, so precision is not possible. The practical conclusion is that JPM’s reported macro sensitivity is far better evidenced by rates, balance-sheet size, and valuation than by any quantified FX line item in the available filings here.
Commodity Exposure Is Mostly Indirect Through Clients, Not Direct Through COGS
COMMODITIESDirect commodity sensitivity looks low in this dataset because JPM is classified as a National Commercial Banks company and the source snapshot provides no COGS line , no input-cost disclosure, and no company-specific commodity hedge schedule. That matters: unlike an airline or chemicals company, the key macro channels here are unlikely to be oil, metals, or agricultural prices flowing directly into gross margin. The more relevant lens is second-order sensitivity through customer activity, borrower health, trading conditions, and credit outcomes...
Trade Policy Risk Exists, but It Is a Credit-and-Activity Channel Rather Than a Tariff Cost Channel
TRADEThe source snapshot does not disclose tariff exposure by product or region , and it does not disclose China supply-chain dependency . For a bank, that already points to the right framing: trade policy is not primarily a bill-of-materials problem, but a second-order macro issue that can affect client volumes, cross-border activity, market sentiment, and borrower credit quality...
quantitative profile
Momentum Score: 55 / 100 (House-derived from +1.4% EPS growth, +2.8% revenue growth, and softer implied Q4 2025 earnings; price-trend series —) · Value Score: 62 / 100 (14.6x P/E, 2.18x price-to-book, and DCF fair value of $330 vs $306 price) · Quality Score: 82 / 100 (31.3% net margin, 15.7% ROE, 1.3% ROA, goodwill equal to 14.5% of equity).
Most important takeaway. JPM’s quant profile is stronger on quality and valuation than on pure growth or momentum. The hard evidence is that ROE was 15.7% and net margin was 31.3% in 2025, yet revenue growth slowed to +2.8% and net income growth was -2.4% , so the stock’s support comes from durability of earnings rather than accelerating operating momentum...
| Factor | Score | Percentile vs Universe | Trend |
|---|---|---|---|
Momentum | 55 / 100 | Estimated 55th percentile AMBER | Deteriorating |
Value | 62 / 100 | Estimated 62nd percentile AMBER | STABLE |
Quality | 82 / 100 | Estimated 82nd percentile GREEN | STABLE |
Size | 99 / 100 | Estimated 99th percentile GREEN | STABLE |
Volatility | 58 / 100 | Estimated 58th percentile AMBER | STABLE |
Growth | 45 / 100 | Estimated 45th percentile AMBER | Deteriorating |
Takeaway. The factor mix is quality-heavy rather than momentum-led. JPM screens best on profitability and scale, but the growth/momentum leg weakened as 2025 revenue growth slowed to 2.8% , net income growth turned -2.4% , and implied Q4 2025 EPS fell to about $4.64 from $5.07-$5.24 in the first three quarters.
| Metric | Value |
|---|---|
Fair Value | $306 |
Market capitalization | $810B |
$10M example position | $10M |
Net income | $57.05B |
2025 year-end equity | $362.44B |
Liquidity Profile
MARKET MICROSTRUCTUREThe source snapshot confirms that JPM closed at $306 on Mar. 26, 2026 , with a market capitalization of $810B and 2.70B shares outstanding at Dec. 31, 2025 ...
| Asset | 1yr Correlation | 3yr Correlation | Rolling 90d Current | Interpretation |
|---|---|---|---|---|
SPY | — | — | — | Return series not provided; beta of 0.94 is the only market-sensitivity input available. |
QQQ | — | — | — | Cannot quantify tech correlation from source data. |
XLF | — | — | — | Sector ETF correlation requires historical returns that are absent from the snapshot. |
BAC | — | — | — | Peer correlation cannot be confirmed because peer price history is not included. |
C | — | — | — | Peer correlation cannot be confirmed because peer price history is not included. |
WFC | — | — | — | Peer correlation cannot be confirmed because peer price history is not included. |
options & derivatives
30-Day IV (%): — (No option chain or live IV series in the source snapshot) · IV Rank (%): — (1-year IV distribution data is not provided) · Put/Call Ratio: — (No listed-options volume or open-interest feed included).
Most important takeaway. The key non-obvious issue is not an overheated options setup but a data-quality mismatch: JPM delivered very steady disclosed quarterly net income of $14.64B in Q1 2025, $14.99B in Q2 2025, and $14.39B in Q3 2025, yet the provided Monte Carlo output shows 0.0% probability of upside. For derivatives work, that means model-driven screens may overstate tail risk relative to the underlying earnings stability actually seen in the available filings.
| Metric | Value |
|---|---|
Q1 2025 net income | $14.64B |
Net income | $14.99B |
Net income (2) | $14.39B |
Net income (3) | $57.05B |
Net income (4) | $182.45B |
Revenue | $20.02 |
Revenue (2) | 15.7% |
EPS | 31.3% |
Implied Volatility Context: Fundamental Stability, But No Confirmed IV Read
DATA-LIMITEDThe source snapshot does not disclose JPM's current 30-day implied volatility, 1-year IV average, IV percentile, or realized-volatility series , so a strict implied-versus-realized comparison cannot be confirmed. That limitation matters because any conclusion that volatility is rich or cheap would normally require the live option chain and a clean trailing volatility history. In this case, the more reliable anchor is the company’s audited earnings pattern from SEC filings rather than a missing derivatives feed...
$391
Bull case if premium returns and valuation both hold
$250
Bear case if earnings normalize and the premium multiple compresses
| Metric | Value |
|---|---|
Net income FY2025 | $57.05B |
Diluted EPS FY2025 | $20.02 |
Net margin FY2025 | 31.3% |
ROE FY2025 | 15.7% |
P/E | 14.6x |
Price-to-book | 2.18x |
Shareholders' equity FY2024 | $344.76B |
Shareholders' equity FY2025 | $362.44B |
governance & accounting
Board Independence: — (Board roster and independence data are not provided in the source snapshot) · Avg Board Tenure: — (Director tenure data are not provided in the source snapshot) · CEO Pay Ratio: — (Executive compensation disclosure is not included in the provided snapshot).
Most important takeaway. The non-obvious signal is that per-share results looked cleaner than absolute profit growth: diluted EPS was $20.02 in 2025 versus basic EPS of $20.05 , but the same year showed net income growth of -2.4% while shares outstanding fell from 2.80B to 2.70B . That combination suggests reported EPS resilience was helped by capital management, not purely by stronger operating conversion, which matters for judging the quality of earnings support.
| Name / Field | Independent | Tenure (years) | Key Committees | Other Board Seats | Relevant Expertise |
|---|---|---|---|---|---|
Board roster disclosure | — | — | — | — | The provided source snapshot contains no director list or expertise matrix… |
Independence status | — | — | — | — | No DEF 14A board-independence detail is included in the snapshot… |
Committee composition | — | — | Audit / compensation / risk committees not provided… | — | Committee membership cannot be assessed from the available filings snapshot… |
Average tenure | — | — | — | — | Tenure data required for refreshment analysis are absent… |
Chair / CEO split or lead director | — | — | — | — | Leadership structure is not described in the snapshot… |
Shareholder Rights Assessment
ADEQUATE / INCOMPLETEThe provided source snapshot does not disclose whether JPMorgan Chase & Co has a poison pill, a classified board, dual-class shares, majority versus plurality voting, proxy access, or a recent shareholder proposal record. Because those items are missing, the shareholder-rights read cannot be scored with the same confidence as the accounting read. In practical terms, that means investors should resist over-interpreting governance quality from strong earnings alone...
| Name | Title | Base Salary | Bonus | Equity Awards | Total Comp | Comp vs TSR Alignment |
|---|---|---|---|---|---|---|
Chief Executive Officer | — in provided snapshot | — | — | — | — | Cannot assess; pay disclosure absent MISSING |
Chief Financial Officer | — in provided snapshot | — | — | — | — | Cannot assess; pay disclosure absent MISSING |
Other Named Executive Officers | — in provided snapshot | — | — | — | — | Cannot assess; pay disclosure absent MISSING |
Accounting Quality Deep-Dive
WATCHThe accounting picture is mixed but not overtly alarming . On the positive side, reported figures are internally coherent: revenue increased from $177.56B in 2024 to $182.45B in 2025 , 2025 net income was $57.05B , and diluted EPS was $20.02 versus basic EPS of $20.05 . That very small EPS gap reduces concern that complex securities or dilution materially distorted per-share reporting...
| Dimension | Score (1-5) | Evidence Summary |
|---|---|---|
Capital Allocation | 4 | Shares outstanding declined from 2.80B at 2024-12-31 to 2.70B at 2025-12-31 while shareholders' equity rose from $344.76B to $362.44B, indicating active capital management that supported per-share results. |
Strategy Execution | 4 | Revenue increased from $177.56B in 2024 to $182.45B in 2025 and net margin remained 31.3%, though net income growth was -2.4%, so execution was strong but not flawless. |
Communication | 3 | The numerical filings snapshot is coherent, but key governance disclosures such as board structure, compensation design, auditor commentary, and rights provisions are not available here, limiting transparency for this pane. |
Culture | 3 | No direct culture or conduct disclosures are provided in the source snapshot. Stable quarterly profitability through most of 2025 is a modest positive, but culture cannot be robustly inferred from financials alone. |
Track Record | 4 | 2025 net income was $57.05B, ROE was 15.7%, ROA was 1.3%, and diluted EPS was $20.02. Those are strong outcomes, even with a year-over-year net income decline of 2.4%. |
Alignment | 3 | Alignment is only partially visible. The share count reduction is shareholder-friendly, but CEO pay ratio, long-term incentive mix, ownership guidelines, and clawback specifics are — in the provided snapshot. |
value framework
This pane applies a bank-adjusted Graham screen, a Buffett-style qualitative checklist, and a cross-check of earnings/book-based valuation against the provided DCF outputs. On the available filings and deterministic models, JPM screens as a high-quality but not classic deep-value bank : the stock at $306 is below the model base fair value of $330 , but the premium 2.18x price-to-book and only moderate 10.6% margin of safety keep the conclusion at Neutral, moderate conviction rather than aggressive overweight.
Important takeaway. JPM looks optically expensive on book at 2.18x , but the more relevant signal is that its 15.7% ROE exceeds the modeled 9.4% cost of equity by 6.3 percentage points . That excess-return spread is the clearest evidence that the premium multiple is tied to franchise quality rather than simple balance-sheet leverage, which is why the stock can still be mildly undervalued even without screening as a traditional Graham bargain.
| Criterion | Threshold | Actual Value | Pass/Fail |
|---|---|---|---|
Adequate size | Large, established enterprise; for banks, clearly systemically relevant scale… | Market cap $810B; total assets $4.42T; revenue $182.45B… | PASS |
Strong financial condition | Conservative balance sheet; bank-adjusted screen still requires strong capitalization and not excessive leverage… | Debt/Equity 0.74; Total Liabilities/Equity 11.21; shareholder equity $362.44B… | FAIL |
Earnings stability | No deficit over a long period, typically 10 years… | 2025 net income $57.05B; Q1-Q3 2025 net income $14.64B, $14.99B, $14.39B, but 10-year series —… | FAIL |
Dividend record | Uninterrupted dividends for at least 20 years… | Dividend data — | FAIL |
Earnings growth | Meaningful long-term EPS growth, traditionally at least one-third over 10 years… | Diluted EPS $20.02; EPS growth YoY +1.4%; long-term 10-year growth —… | FAIL |
Moderate P/E | P/E <= 15 | P/E 14.6 | PASS |
Biggest caution. Graham-style value investors should not ignore that JPM fails the cheap-on-book test with a 2.18x price-to-book and carries 11.21x total liabilities to equity . Those numbers do not make the stock uninvestable, but they do mean the thesis depends on sustained superior returns on capital rather than mean reversion to a classic bank discount.
| Metric | Value |
|---|---|
Buffett quality score | 17/20 |
Revenue FY2025 | $182.45B |
Net income FY2025 | $57.05B |
Diluted EPS FY2025 | $20.02 |
Q1 2025 net income | $14.64B |
Q2 2025 net income | $14.99B |
Q3 2025 net income | $14.39B |
Understandable business score | 4/5 |
Buffett Qualitative Assessment
QUALITY CHECKUsing Buffett’s four-part lens, JPM scores 17/20 , which supports a B+ quality grade. The business is highly understandable for a diversified bank: the filings show a franchise that converted $182.45B of 2025 revenue into $57.05B of net income and $20.02 of diluted EPS. Even with the usual complexity of a global financial institution, the core economic engine is visible in the reported numbers: scale, fee breadth, funding advantage, and disciplined capital return...
| Bias | Risk Level | Mitigation Step | Status |
|---|---|---|---|
Anchoring to book value | HIGH | Focus on ROE 15.7% versus cost of equity 9.4% before judging 2.18x P/B as too expensive… | WATCH |
Confirmation bias | Medium MED | Pair DCF upside with Monte Carlo and operating cash flow inconsistency to test the long case… | WATCH |
Recency bias | Medium MED | Do not extrapolate 2025 profitability blindly; revenue growth slowed to 2.8% and net income growth was -2.4% | WATCH |
Quality halo effect | HIGH | Separate franchise admiration from valuation discipline; only 10.6% margin of safety exists to base fair value… | FLAGGED |
Model overreliance | HIGH | Downweight cash-flow-based outputs because operating cash flow is -$147.782B and Monte Carlo gives 0.0% upside for a bank… | FLAGGED |
Base-rate neglect | Medium MED | Acknowledge that large banks usually rerate when ROE compresses, even if absolute earnings remain high… | WATCH |
See detailed valuation bridge, DCF assumptions, and method cross-check in the Valuation tab.
See the variant perception, moat debate, and catalyst map in the Thesis tab.
appendix & sources
How we source the tape, verify levels, and align this report with XVARY deep-dive standards.
Sources: SEC filings, company disclosures, market data vendors, and sources cited in the sections above. For investment presentation use only.
standards and pipeline: xvary.com/methodology/